A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy.

Trial Profile

A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSERT
  • Sponsors Centocor; Janssen Biotech
  • Most Recent Events

    • 13 Jun 2015 Post hoc analysis (syndesmophyte formation) results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 01 Feb 2009 Results published in Annals of the Rheumatic Diseases.
    • 01 Apr 2008 Results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top